Monte Rosa Therapeutics, Inc. Right-of-Use Asset Obtained in Exchange for Operating Lease Liability
Monte Rosa Therapeutics, Inc. (GLUE) reported Right-of-Use Asset Obtained in Exchange for Operating Lease Liability of $0 for the 12-month period ending 2025-12-31, per its 10-K filed 2026-03-17.
Financial Statements › Notes › Leases
us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability · last filed 2026-03-17
- Monte Rosa Therapeutics, Inc. right-of-use asset obtained in exchange for operating lease liability for the quarter ending 2025-12-31 was $0.00.
- Monte Rosa Therapeutics, Inc. right-of-use asset obtained in exchange for operating lease liability for the quarter ending 2025-09-30 was $0.00.
- Monte Rosa Therapeutics, Inc. right-of-use asset obtained in exchange for operating lease liability for the quarter ending 2025-06-30 was $0.00.
- Monte Rosa Therapeutics, Inc. right-of-use asset obtained in exchange for operating lease liability for the quarter ending 2025-03-31 was $0.00, a 100.00% decline year-over-year.
- Monte Rosa Therapeutics, Inc. right-of-use asset obtained in exchange for operating lease liability for fiscal 2025 was $0.00, a 100.00% decline from fiscal 2024.
- Monte Rosa Therapeutics, Inc. right-of-use asset obtained in exchange for operating lease liability for fiscal 2024 was $108.00K, a 94.23% decline from fiscal 2023.
- Monte Rosa Therapeutics, Inc. right-of-use asset obtained in exchange for operating lease liability for fiscal 2023 was $1.87M, a 96.14% decline from fiscal 2022.
- Monte Rosa Therapeutics, Inc. right-of-use asset obtained in exchange for operating lease liability for fiscal 2022 was $48.49M.
| Period end | Right-of-Use Asset Obtained in Exchange for Operating Lease Liability 3 month | Right-of-Use Asset Obtained in Exchange for Operating Lease Liability 6 month | Right-of-Use Asset Obtained in Exchange for Operating Lease Liability 9 month | Right-of-Use Asset Obtained in Exchange for Operating Lease Liability 12 month |
|---|---|---|---|---|
| 2025-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-17 | $0.00 derived: sum of 2 quarters · filed 2026-03-17 | $0.00 derived: sum of 3 quarters · filed 2026-03-17 | $0.00 10-K · filed 2026-03-17 |
| 2025-09-30 | $0.00 10-Q · filed 2025-11-06 | $0.00 derived: sum of 2 quarters · filed 2025-11-06 | $0.00 10-Q · filed 2025-11-06 | $0.00 derived: sum of 4 quarters · filed 2026-03-17 |
| 2025-06-30 | $0.00 10-Q · filed 2025-08-07 | $0.00 10-Q · filed 2025-08-07 | $0.00 derived: sum of 3 quarters · filed 2026-03-17 | $0.00 derived: sum of 4 quarters · filed 2026-03-17 |
| 2025-03-31 | $0.00 10-Q · filed 2025-05-08 | $0.00 derived: sum of 2 quarters · filed 2026-03-17 | $0.00 derived: sum of 3 quarters · filed 2026-03-17 | $0.00 derived: sum of 4 quarters · filed 2026-03-17 |
| 2024-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-17 | $0.00 derived: sum of 2 quarters · filed 2026-03-17 | $0.00 derived: sum of 3 quarters · filed 2026-03-17 | $108.00K 10-K · filed 2026-03-17 |
| 2024-09-30 | $0.00 10-Q · filed 2025-11-06 | $0.00 derived: sum of 2 quarters · filed 2025-11-06 | $108.00K 10-Q · filed 2025-11-06 | $108.00K derived: sum of 4 quarters · filed 2025-11-06 |
| 2024-06-30 | $0.00 10-Q · filed 2025-08-07 | $108.00K 10-Q · filed 2025-08-07 | $108.00K derived: sum of 3 quarters · filed 2025-08-07 | $108.00K derived: sum of 4 quarters · filed 2025-08-07 |
| 2024-03-31 | $108.00K 10-Q · filed 2025-05-08 | $108.00K derived: sum of 2 quarters · filed 2025-05-08 | $108.00K derived: sum of 3 quarters · filed 2025-05-08 | $1.98M derived: sum of 4 quarters · filed 2025-05-08 |
| 2023-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-20 | $0.00 derived: sum of 2 quarters · filed 2025-03-20 | $1.87M derived: sum of 3 quarters · filed 2025-03-20 | $1.87M 10-K · filed 2025-03-20 |
| 2023-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-07 | $1.87M derived: sum of 2 quarters · filed 2024-11-07 | $1.87M 10-Q · filed 2024-11-07 | $1.87M derived: sum of 4 quarters · filed 2024-11-07 |
| 2023-06-30 | $1.87M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-08 | $1.87M 10-Q · filed 2024-08-08 | $1.87M derived: sum of 3 quarters · filed 2024-08-08 | $1.87M derived: sum of 4 quarters · filed 2024-08-08 |
| 2023-03-31 | $0.00 10-Q · filed 2024-05-09 | $0.00 derived: sum of 2 quarters · filed 2024-05-09 | $0.00 derived: sum of 3 quarters · filed 2024-05-09 | $41.20M derived: sum of 4 quarters · filed 2024-05-09 |
| 2022-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-14 | $0.00 derived: sum of 2 quarters · filed 2024-03-14 | $41.20M derived: sum of 3 quarters · filed 2024-03-14 | $48.49M 10-K · filed 2024-03-14 |
| 2022-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-09 | $41.20M derived: sum of 2 quarters · filed 2023-11-09 | $48.49M 10-Q · filed 2023-11-09 | |
| 2022-06-30 | $41.20M derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-10 | $48.49M 10-Q · filed 2023-08-10 | ||
| 2022-03-31 | $7.29M 10-Q · filed 2023-05-11 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Cullinan Therapeutics, Inc. (CGEM) | United States | $0.993B | -5.72 |
| Odyssey Therapeutics, Inc. (ODTX) | United States | $0.960B | |
| MeiraGTx Holdings plc (MGTX) | United States | $1.061B | 16.10 |
| Vor Biopharma Inc. (VOR) | United States | $1.091B | 1.60 |
| Sana Biotechnology, Inc. (SANA) | United States | $0.886B | -4.92 |
| Candel Therapeutics, Inc. (CADL) | United States | $0.885B | -8.86 |
| Attovia Therapeutics, Inc. (ATTO) | United States | $0.828B | |
| Replimune Group, Inc. (REPL) | United States | $1.186B | -3.13 |
| Solid Biosciences Inc. (SLDB) | United States | $0.802B | -5.07 |
| 4D Molecular Therapeutics, Inc. (FDMT) | United States | $0.733B | -4.10 |